Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Harvard University · Dana-Farber Cancer Institute · +4 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,483
total citations
- FWCI
- 49.61
- Percentile
- 100%
- References
- 71
Citations per year
Authors
21- EWEllen WeisbergCorresponding
Harvard University, Dana-Farber Cancer Institute
- PWPaul W. Manley
Novartis (Switzerland), Novartis Institutes for BioMedical Research
- WBWerner Breitenstein
Novartis (Switzerland), Novartis Institutes for BioMedical Research
- JBJosef Brüggen
Novartis (Switzerland), Novartis Institutes for BioMedical Research
- SWSandra W. Cowan‐Jacob
Novartis (Switzerland), Novartis Institutes for BioMedical Research
Topics & keywords
Topics
Keywords
- Mutant
- Cancer research
- Mutation
- Chemistry
- Cell biology
- Biology
- Biochemistry
- Gene
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.